[
  {
    "ts": null,
    "headline": "Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating",
    "summary": "Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=875a53d3d17f3991b2caeb7e5a5814b08dfee064061d5f713a2aa9203a132a48",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738768125,
      "headline": "Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating",
      "id": 132565449,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=875a53d3d17f3991b2caeb7e5a5814b08dfee064061d5f713a2aa9203a132a48"
    }
  },
  {
    "ts": null,
    "headline": "Dow up 264 points on gains for Amgen, NVIDIA Corp. shares",
    "summary": "Dow up 264 points on gains for Amgen, NVIDIA Corp. shares",
    "url": "https://finnhub.io/api/news?id=14522b0ead6971c45a7d15acc074a34c685995d64c40e7b4752770b363481809",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738764480,
      "headline": "Dow up 264 points on gains for Amgen, NVIDIA Corp. shares",
      "id": 132564061,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow up 264 points on gains for Amgen, NVIDIA Corp. shares",
      "url": "https://finnhub.io/api/news?id=14522b0ead6971c45a7d15acc074a34c685995d64c40e7b4752770b363481809"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Is Playing Defense With Capital Allocation",
    "summary": "Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.",
    "url": "https://finnhub.io/api/news?id=9a0c9b25731d76b789ce893a51dade7a12e0b641dc763a1ebb21f152d7bed54c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738761030,
      "headline": "Regeneron Is Playing Defense With Capital Allocation",
      "id": 132563616,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2129856936/image_2129856936.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.",
      "url": "https://finnhub.io/api/news?id=9a0c9b25731d76b789ce893a51dade7a12e0b641dc763a1ebb21f152d7bed54c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb",
    "summary": "Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb",
    "url": "https://finnhub.io/api/news?id=4cd443e114c79cbc979e50a14141aa0503528955326bdd3ab0714973ab0a7ecc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738756320,
      "headline": "Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb",
      "id": 132564063,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb",
      "url": "https://finnhub.io/api/news?id=4cd443e114c79cbc979e50a14141aa0503528955326bdd3ab0714973ab0a7ecc"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs",
    "summary": "Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs",
    "url": "https://finnhub.io/api/news?id=c12b4071d5b7cee405b563bd5a1519bec9dd57d2cabc2b8829e32cee10af15e9",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738749881,
      "headline": "Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs",
      "id": 132566414,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs",
      "url": "https://finnhub.io/api/news?id=c12b4071d5b7cee405b563bd5a1519bec9dd57d2cabc2b8829e32cee10af15e9"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: EPS up 13% in Q4",
    "summary": "Amgen reported adjusted EPS for the last three months of 2024 up 13% to $5.31, with non-GAAP operating margin down 0.4 points to 46.3% but revenues up 11% to $9.1 billion.Product sales were up 11%,...",
    "url": "https://finnhub.io/api/news?id=e686ed39767a22281a563b18f2350ac54aca92a23f7343bdb8a4efefd6b8d17e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738725856,
      "headline": "Amgen: EPS up 13% in Q4",
      "id": 132559616,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen reported adjusted EPS for the last three months of 2024 up 13% to $5.31, with non-GAAP operating margin down 0.4 points to 46.3% but revenues up 11% to $9.1 billion.Product sales were up 11%,...",
      "url": "https://finnhub.io/api/news?id=e686ed39767a22281a563b18f2350ac54aca92a23f7343bdb8a4efefd6b8d17e"
    }
  }
]